ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18, 2024
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
December 17, 2024
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
December 16, 2024
APDN Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
October 30, 2024
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
October 15, 2024
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 18, 2024
Linea IVT as High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA
September 17, 2024
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
September 17, 2024
Get Social